Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quantitative Muscle Ultrasound as a Marker of Progression in Children With Muscular Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03786913
Recruitment Status : Completed
First Posted : December 25, 2018
Last Update Posted : February 8, 2019
Sponsor:
Information provided by (Responsible Party):
Waleed Ahmed Salaheldeen Hassan, Benha University

Brief Summary:
The aim of our study is to Assess skeletal muscle structural status in children with inflammatory myositis and Duchenne muscular dystrophy using musculoskeletal ultrasound and to perform a longitudinal follow up of these changes over 2 years and to assess the relation between these findings with clinical parameters, functional scales, biochemical and electromyographic tests.

Condition or disease Intervention/treatment
Inflammatory Myopathy Duchenne Muscular Dystrophy Diagnostic Test: Quantitative muscle ultrasound measurements

Detailed Description:

This study will be carried out on two groups:

• Group (I): fifty children diagnosed to have duchenne muscular dystrophy and inflammatory myositis.

Group (II): including 20 healthy children matching age and sex as control group.

patients will be subjected to

(A) Clinical evaluation

  1. Complete history taking.
  2. Thorough clinical examination.
  3. Body mass index (BMI) assessment.
  4. Quantitative muscle strength tests
  5. Functional grading
  6. Childhood Myositis Assessment Scale. 7 (B) Laboratory assessment:

All patients will be subjected to the following measurements:

  1. Serum creatine kinase levels (CK).
  2. Serum Lactate dehydrogenase levels
  3. Serum of Liver enzymes (SGOT& SGPT) levels.

(C) Electromyographic (EMG) assessment:

(D) Musculoskeletal ultrasound assessment (E) Statistical analysis


Layout table for study information
Study Type : Observational
Actual Enrollment : 48 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Quantitative Muscle Ultrasound as a Monitoring Tool of Disease Progression in Children With Inflammatory Myositis and Duchenne Muscular Dystrophy
Actual Study Start Date : March 8, 2016
Actual Primary Completion Date : February 2, 2019
Actual Study Completion Date : February 2, 2019


Group/Cohort Intervention/treatment
children with muscle disease
fifty children diagnosed to have inflammatory myositis or Duchenne muscular dystrophy in whom Quantitative muscle ultrasound measurements will be performed .The captured images will be analyzed for echo intensity by means of computer-assisted grayscale histogram analysis at baseline and after 24 months.
Diagnostic Test: Quantitative muscle ultrasound measurements
Quantitative ultrasound measurements will be performed to biceps, forearm flexors, quadriceps and tibialis anterior according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.

control group
20 healthy children matching age and sex as control group in whom Quantitative muscle ultrasound measurement will be performed at baseline
Diagnostic Test: Quantitative muscle ultrasound measurements
Quantitative ultrasound measurements will be performed to biceps, forearm flexors, quadriceps and tibialis anterior according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.




Primary Outcome Measures :
  1. Kendall's manual muscle testing [ Time Frame: 24 months ]
    Kendall's 0 -10 point scale measures strength of each muscle group score 0 is the weakest (worst) and 10 is the strongest (best). The following muscles were tested bilaterally: the biceps brachii muscle (BB), the forearm flexors (FF), the rectus femoris muscle (RF), the tibialis anterior muscle (TA)

  2. Childhood myositis assessment scale [ Time Frame: 24 months ]
    used to assess the severity of muscle involvement in children with dermatomyositis. The scores for the 14 items are summated to give a total score ranging from 0 (worst) to 52 (best)

  3. Serum creatine kinase (CK) levels [ Time Frame: 24 months ]
    CK measured in U/L using ELISA

  4. Serum Lactate dehydrogenase (LDH) levels [ Time Frame: 24 months ]
    CK measured in IU/L using ELISA

  5. Aspartate aminotransferase (AST) [ Time Frame: 24 MONTHS ]
    AST measured in U/L using ELISA

  6. alanine aminotransferase (ALT) [ Time Frame: 24 months ]
    ALT measured in U/L using ELISA

  7. motor unit potential (MUP) duration [ Time Frame: 24 months ]
    quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the MUP duration measured in milliseconds.

  8. motor unit peak-to-peak amplitude [ Time Frame: 24 months ]
    quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the peak-to-peak amplitude measured in microvolt

  9. motor unit area to amplitude ratio (AAR) [ Time Frame: 24 months ]
    quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the motor unit AAR .



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
the study will be performed on 2 groups Group (I): fifty children diagnosed to have inflammatory myositis and Duchenne muscular dystrophy Group (II): including 20 healthy children matching age and sex as control group.
Criteria

Inclusion Criteria:

  • children with Duchenne muscular dystrophy (DMD). Diagnosis with DMD was established according to DMD diagnostic criteria (Jennekens et al., 1991).
  • children with juvenile dermatomyositis (JDM) according to Bohan and Peter diagnostic criteria ( (Bohan and Peter, 1975).

Exclusion Criteria:

  • Patients with age less than 2 years were excluded from the study due to inability to perform manual muscle testing and functional scales.
  • If no final diagnosis could be established.
  • The presence of a concomitant illness that may result in peripheral neuropathy or myopathy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03786913


Locations
Layout table for location information
Egypt
Benha University Hospital
Banhā, Qalubiya, Egypt, 13518
Sponsors and Collaborators
Benha University
Investigators
Layout table for investigator information
Principal Investigator: Waleed Hassan, MD Benha university- Qaluibya- Egypt

Layout table for additonal information
Responsible Party: Waleed Ahmed Salaheldeen Hassan, Assistant professor, Benha University
ClinicalTrials.gov Identifier: NCT03786913     History of Changes
Other Study ID Numbers: BenhaU122018
First Posted: December 25, 2018    Key Record Dates
Last Update Posted: February 8, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Waleed Ahmed Salaheldeen Hassan, Benha University:
Inflammatory myositis
Duchenne Muscular Dystrophy
Musculoskeletal ultrasound
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Myositis
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked